This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (153)  • Contact me when this article is cited  Related Content  • Related letters  • Related article  • Similar articles in JAMA  Topic Collections  • Bacterial Infections  • Pulmonary Diseases  • Pneumonia  • Gastroenterology  • Gastrointestinal Diseases  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Robert J. F. Laheij, PhD; Miriam C. J. M. Sturkenboom, PhD; Robert-Jan Hassing, MSc; Jeanne Dieleman, PhD; Bruno H. C. Stricker, MD, PhD; Jan B. M. J. Jansen, MD, PhD

JAMA. 2004;292:1955-1960.

Context  Reduction of gastric acid secretion by acid-suppressive therapy allows pathogen colonization from the upper gastrointestinal tract. The bacteria and viruses in the contaminated stomach have been identified as species from the oral cavity.

Objective  To examine the association between the use of acid-suppressive drugs and occurrence of community-acquired pneumonia.

Design, Setting, and Participants  Incident acid-suppressive drug users with at least 1 year of valid database history were identified from the Integrated Primary Care Information database between January 1, 1995, and December 31, 2002. Incidence rates for pneumonia were calculated for unexposed and exposed individuals. To reduce confounding by indication, a case-control analysis was conducted nested in a cohort of incident users of acid-suppressive drugs. Cases were all individuals with incident pneumonia during or after stopping use of acid-suppressive drugs. Up to 10 controls were matched to each case for practice, year of birth, sex, and index date. Conditional logistic regression was used to compare the risk of community-acquired pneumonia between use of proton pump inhibitors (PPIs) and H₂-receptor antagonists.

Main Outcome Measure  Community-acquired pneumonia defined as certain (proven by radiography or sputum culture) or probable (clinical symptoms consistent with pneumonia).

Results  The study population comprised 364 683 individuals who developed 5551 first occurrences of pneumonia during follow-up. The incidence rates of pneumonia in non–acid-suppressive drug users and acid-suppressive drug users were 0.6 and 2.45 per 100 person-years, respectively. The adjusted relative risk for pneumonia among persons currently using PPIs compared with those who stopped using PPIs was 1.89 (95% confidence interval, 1.36-2.62). Current users of H₂-receptor antagonists had a 1.63-fold increased risk of pneumonia (95% confidence interval, 1.07-2.48) compared with those who stopped use. For current PPI users, a significant positive dose-response relationship was observed. For H₂-receptor antagonist users, the variation in dose was restricted.

Conclusion  Current use of gastric acid–suppressive therapy was associated with an increased risk of community-acquired pneumonia.

Author Affiliations: Department of Gastroenterology, University Medical Center St. Radboud, Nijmegen, the Netherlands (Drs Laheij and Jansen); and Department of Medical Informatics (Drs Laheij, Sturkenboom, Dieleman, and Stricker and Mr Hassing), Pharmacoepidemiology Unit, Department of Epidemiology and Biostatistics (Drs Sturkenboom and Stricker), and Internal Medicine (Dr Dieleman), Erasmus MC University, Medical Center Rotterdam, Rotterdam, the Netherlands.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Community-Acquired Pneumonia and Use of Gastric Acid–Suppressive Drugs
Robert T. Sataloff
JAMA. 2005;293(7):795-796.
EXTRACT | FULL TEXT  

Community-Acquired Pneumonia and Use of Gastric Acid–Suppressive Drugs—Reply
Robert J. F. Laheij, Miriam C. J. M. Sturkenboom, Jeanne Dieleman, Bruno H. C. Stricker, and Jan B. M. J. Jansen
JAMA. 2005;293(7):796.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Acid Suppression and Pneumonia: A Clinical Indication for Rational Prescribing
James C. Gregor
JAMA. 2004;292(16):2012-2013.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Nosocomial Pneumonia Risk and Stress Ulcer Prophylaxis: A Comparison of Pantoprazole vs Ranitidine in Cardiothoracic Surgery Patients
Miano et al.
Chest 2009;136:440-447.
ABSTRACT | FULL TEXT  

Esomeprazole for asthma.
Hsu et al.
NEJM 2009;361:206-207.
FULL TEXT  

Acid-Suppressive Medication Use and the Risk for Hospital-Acquired Pneumonia
Herzig et al.
JAMA 2009;301:2120-2128.
ABSTRACT | FULL TEXT  

Bronchopulmonary Actinomycosis Associated With Hiatal Hernia
Andreani et al.
Mayo Clin Proc. 2009;84:123-128.
ABSTRACT | FULL TEXT  

Impact of poor dental health on pneumonia
Wise et al.
Eur Respir J 2008;32:1123-1124.
FULL TEXT  

Proton-Pump Inhibitor Use and the Risk for Community-Acquired Pneumonia
Sarkar et al.
ANN INTERN MED 2008;149:391-398.
ABSTRACT | FULL TEXT  

Use of proton pump inhibitors and risk of osteoporosis-related fractures
Targownik et al.
CMAJ 2008;179:319-326.
ABSTRACT | FULL TEXT  

Cost-effectiveness of Proton Pump Inhibitor Cotherapy in Patients Taking Long-term, Low-Dose Aspirin for Secondary Cardiovascular Prevention
Saini et al.
Arch Intern Med 2008;168:1684-1690.
ABSTRACT | FULL TEXT  

The Effect of Subchronic Administration of 7-(4-Fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methylcyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526), a Novel Acid Pump Antagonist, on Gastric Acid Secretion and Gastrin Levels in Rats
Ito et al.
J. Pharmacol. Exp. Ther. 2008;326:163-170.
ABSTRACT | FULL TEXT  

A 32-Year-Old Woman With Chronic Abdominal Pain
Lacy and Cash
JAMA 2008;299:555-565.
ABSTRACT | FULL TEXT  

Potential Influence of Antisecretory Therapy on the Development of Candida-Associated Intraabdominal Infection
Cat et al.
The Annals of Pharmacotherapy 2008;42:185-191.
ABSTRACT | FULL TEXT  

Inappropriate Continuation of Stress Ulcer Prophylactic Therapy After Discharge
Wohlt et al.
The Annals of Pharmacotherapy 2007;41:1611-1616.
ABSTRACT | FULL TEXT  

Consensus Statement for Standard of Care in Spinal Muscular Atrophy
Wang et al.
J Child Neurol 2007;22:1027-1049.
ABSTRACT  

Stress ulcer prophylaxis in hospitalized patients not in intensive care units
Grube and May
Am J Health Syst Pharm 2007;64:1396-1400.
ABSTRACT | FULL TEXT  

Use of Proton Pump Inhibitors and the Risk of Community-Acquired Pneumonia: A Population-Based Case-Control Study
Gulmez et al.
Arch Intern Med 2007;167:950-955.
ABSTRACT | FULL TEXT  

Statin treatment and reduced risk of pneumonia in patients with diabetes
van de Garde et al.
Thorax 2006;61:957-961.
ABSTRACT | FULL TEXT  

Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy.
Dial et al.
CMAJ 2006;175:745-748.
ABSTRACT | FULL TEXT  

Acid Suppressive Therapy Use on an Inpatient Internal Medicine Service
Pham et al.
The Annals of Pharmacotherapy 2006;40:1261-1266.
ABSTRACT | FULL TEXT  

The systems biology of infection in animal models bears fruit
Hoffman and Miller
Proc. Natl. Acad. Sci. USA 2006;103:9377-9378.
FULL TEXT  

From the Cover: Histamine signaling through the H2 receptor in the Peyer's patch is important for controlling Yersinia enterocolitica infection
Handley et al.
Proc. Natl. Acad. Sci. USA 2006;103:9268-9273.
ABSTRACT | FULL TEXT  

Angiotensin-converting enzyme inhibitor use and pneumonia risk in a general population
van de Garde et al.
Eur Respir J 2006;27:1217-1222.
ABSTRACT | FULL TEXT  

Therapy With Gastric Acidity Inhibitors Increases the Risk of Acute Gastroenteritis and Community-Acquired Pneumonia in Children
Canani et al.
Pediatrics 2006;117:e817-e820.
ABSTRACT | FULL TEXT  

Association of H2-Blocker Therapy and Higher Incidence of Necrotizing Enterocolitis in Very Low Birth Weight Infants
Guillet et al.
Pediatrics 2006;117:e137-e142.
ABSTRACT | FULL TEXT  

Chronic Cough Due to Gastroesophageal Reflux Disease: ACCP Evidence-Based Clinical Practice Guidelines
Irwin
Chest 2006;129:80S-94S.
ABSTRACT | FULL TEXT  

Use of Gastric Acid-Suppressive Agents and the Risk of Community-Acquired Clostridium difficile-Associated Disease
Dial et al.
JAMA 2005;294:2989-2995.
ABSTRACT | FULL TEXT  

Are US flu death figures more PR than science?
Doshi
BMJ 2005;331:1412-1412.
FULL TEXT  

Proton Pump Inhibitor Formulary Considerations in the Acutely Ill Part 2: Clinical Efficacy, Safety, and Economics
Devlin et al.
The Annals of Pharmacotherapy 2005;39:1844-1851.
ABSTRACT | FULL TEXT  

Effectiveness of the 2003-2004 Influenza Vaccine Among Children 6 Months to 8 Years of Age, With 1 vs 2 Doses
Ritzwoller et al.
Pediatrics 2005;116:153-159.
ABSTRACT | FULL TEXT  

An increased risk of community acquired pneumonia with gastric acid suppressive drug therapy
Parker
Thorax 2005;60:192-192.
FULL TEXT  

Community-Acquired Pneumonia and Use of Gastric Acid-Suppressive Drugs
Sataloff
JAMA 2005;293:795-796.
FULL TEXT  

JournalScan
Gut 2005;54:307-307.
FULL TEXT  

Gastric acid suppression is associated with increased risk of pneumonia
BMJ 2005;330:.
FULL TEXT  

Acid-Suppressive Drugs and Risk for Pneumonia
JWatch Gastroenterology 2004;2004:5-5.
FULL TEXT  

Gastric Acid Suppressants Increase the Risk for Community-Acquired Pneumonia
JWatch Infect. Diseases 2004;2004:3-3.
FULL TEXT  

Gastric Acid Suppression Linked with Risk for Pneumonia
JWatch General 2004;2004:4-4.
FULL TEXT  

Acid Suppression and Pneumonia: A Clinical Indication for Rational Prescribing
Gregor
JAMA 2004;292:2012-2013.
FULL TEXT